EGFR and glioblastoma: In the context of cancer, MV vectors expressing CD46 and signaling lymphocyte activation molecule (SLAM) combined with a single-chain antibody against epidermal growth factor receptor (EGFR) at the C terminus of HA were retargeted to EGFR- or EGFRvIII primary glioblastoma cell lines and further caused tumor regression and prolonged the survival of mice with glioblastoma xenografts [105].